Researchers at the Institute for Molecular Bioscience (IMB) at The University of Queensland (UQ) have developed a platform technology that cyclises conotoxin derived from sea snail venom.
Conotoxins are small peptides in the order of 20 amino acids that target different receptors and ion channels with exquisite specificity and selectivity. The platform enables conotoxin-derived peptide drugs to be more stable and orally bio-available without compromising specificity or functionality. The platform technology has generated a lead compound (IMB007) which is an orally active peptide that has the potential to be a neuropathic pain treatment.

UniQuest Contact: 

Mark Ashton

Position: 
Executive Director, Intellectual Property Commercialisation
Mobile phone: 
+61 410 601 970
Work phone: 
+61 (7) 3365 4037